Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akari TherapeuticsSTU:CLA1 30 Days Payable is 0.00 as of Jun. 2026. GuruFocus rates STU:CLA1 with a GF Score™ of 30/100. Among 704 Biotechnology companies, Akari Therapeutics ranks worse than 142045.31% on this metric.
The historical rank and industry rank for Akari Therapeutics's Days Payable or its related term are showing as below:
STU:CLA1's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 110.01 * Ranked among companies with meaningful Days Payable only.
Akari Therapeutics's Days Payable
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
stayed the same
The historical data trend for Akari Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CLA1 vs MBRX, INTI, TPST: Days Payable Comparison
For the Biotechnology subindustry, Akari Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akari Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Akari Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Akari Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akari Therapeutics (STU:CLA1) has a Days Payable of 0.00 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Akari Therapeutics and its competitors. According to the industry distribution chart, Akari Therapeutics ranks #999999 out of 704 companies in the Biotechnology industry.
Is Akari Therapeutics' Days Payable too high?
Akari Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Akari Therapeutics ranks #999999 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Akari Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' Days Payable compare to MBRX and INTI?
According to the Biotechnology industry distribution chart, Akari Therapeutics ranks #999999 out of 704 companies for Days Payable. This places Akari Therapeutics in the lower half of its industry. The industry median Days Payable is 110.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Akari Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akari Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (STU:CLA1) has a current Days Payable of 0.00. The current Days Payable is 0.00. Akari Therapeutics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Akari Therapeutics (STU:CLA1), the current Days Payable is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
30GF Score
Get the complete analysis for STU:CLA1
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CLA1 has been successfully added to your 
